SCHEMBL3218969

SCHEMBL3218969

Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1Nc1nccc(-c2cccnc2)n1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 13/20 0.71
BCR P11274 11/20 0.71
PDGFRA P16234 11/20 0.71
PDGFRB P09619 6/20 0.71
EGFR P00533 2/20 0.69
PRKCA P17252 1/20 0.69
TEK Q02763 1/20 0.67
MAPK14 Q16539 3/20 0.64
KIT P10721 6/20 0.64
PLK4 O00444 1/20 0.63
DDX3X O00571 1/20 0.63
GAK O14976 1/20 0.63
SLC22A2 O15244 1/20 0.63
MAPK13 O15264 1/20 0.63
CA12 O43570 1/20 0.63
SLC22A3 O75751 1/20 0.63
ABCB11 O95342 1/20 0.63
CA1 P00915 1/20 0.63
CA2 P00918 1/20 0.63
LMNA P02545 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13492423 0.93 ABL1 (0.74) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL13492427 0.92 ABL1 (0.73) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL13492422 0.92 ABL1 (0.73) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL13492358 0.92 MAPK14 (0.64) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL13492424 0.92 ABL1 (0.70) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL13492383 0.89 MAPK14 (0.60) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL13492371 0.89 MAPK14 (0.60) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL13492316 0.88 ABL1 (0.68) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL13492417 0.86 PDGFRA (0.68) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL5223561 0.86 ABL1 (0.73) ABL1BCRPDGFRAPDGFRBEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048539-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-25 US claimed
EP-2079729-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-07-22 EP claimed
WO-2008058037-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-05-15 WO claimed
US-20100048539-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-25 US disclosed
US-20100048539-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-25 US disclosed
US-20100048539-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-25 US disclosed
EP-2079729-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-07-22 EP disclosed
WO-2008058037-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-05-15 WO disclosed
WO-2008058037-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048539-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS PDGFRB, PDGFRA, KIT ABL1 9/4885BCR 65/4885PDGFRA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.